Servier

Servier and Owkin Join Forces to Harness AI for Targeted Therapies in Disease Treatment

(IN BRIEF) Servier, a global pharmaceutical group, has partnered with Owkin, a biotech company specializing in AI-driven drug discovery and…

7 months ago

QIAGEN and Servier Collaborate to Develop Diagnostic Test for Hard-to-Treat Blood Cancer

(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for…

1 year ago

Symplmed Pharmaceuticals announced the FDA approval of Prestalia® for the treatment of hypertension licensed from Servier

Cincinnati, OH, 28-1-2015 — /EuropaWire/ — Symplmed Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine…

9 years ago

Servier and Hybrigenics extend partnership to discover new drugs which inhibit Ubiquitin-Specific Proteases (USPs)

PARIS, 28-1-2015 — /EuropaWire/ — Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus…

9 years ago

European pharmaceutical company Servier partners with Walter and Eliza Hall Institute to develop new agents that could be effective in treating several types of cancer

Melbourne, Australia and Suresnes, France, 2-10-2014 — /EuropaWire/ — The European pharmaceutical company Servier has established a collaborative partnership with the Walter…

10 years ago

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating…